Sight Sciences (Nasdaq:SGHT) announced today that 36-month data supports the use of its Omni surgical system.
Data from the three-year post-surgery follow-up demonstrates that the Omni surgical system delivers safe, consistent and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basement.
Menlo Park, California-based Sight Sciences evaluated the Omni system in canaloplasty followed by trabeculectomy, with the system achieving a mean reduction in intraocular pressure (IOP) of at least 20 percent for all 26 patients (38 eyes) at 36 months follow-up.
Post-operative IOP and medication use reduction at 12 months remained consistent over the three years, suggesting robust, durable effectiveness when used as a standalone intervention in either phakic or pseudophakic eyes, according to a news release.
Sight Sciences received reports of a “minimal number” of adverse events, all of which were resolved without any intervention apart from one eye that required secondary IOP lowering intervention.
Dr. Karsten Klabe, the study’s principal investigator and the head surgeon at Breyer, Kaymak & Klabe Augenchirurgie in Germany, said in the release that the Omni system could offer long-standing benefits to OAG patients, “transforming how glaucoma is cared for.”
“The Omni surgical system is supported by a robust clinical development program, which includes this treatment evaluation over three years in patients with open-angle glaucoma,” Sight Sciences co-founder and CEO Paul Badawi said in the release. “These results highlight the long-term effectiveness and strong safety profile of the Omni surgical system. This non-implantable procedure has shown effectiveness without the known IOP-lowering assistance of cataract surgery.
“We look forward to ongoing data collection and evaluating the durability at further intervals post-microinvasive canal surgery with Omni.”